small molecule

ZOLPIMIST

ZOLPIDEM TARTRATE

Loss of exclusivityAugust 2032latest FDA-listed patent expiry
CompanyAYTU BIOSCIENCE INC

Drug detail

Brand nameZOLPIMIST
Active ingredientZOLPIDEM TARTRATE
Strength5MG/SPRAY
Dosage formSPRAY, METERED
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2008
Marketing statusDISCN

Listed patents

PatentExpiresType
8236285August 2032substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZOLPIMIST patent cliff — loss of exclusivity August 2032 | CliffBio